CSRXP APPLAUDS U.S. HOUSE PROBE INTO BIOGEN PRICING OF ADUHELM

Pallone and Maloney Announce Joint Investigation into Massive Price Tag on Unproven Alzheimer’s Treatment as Outrage Builds

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Friday on the announcement of a joint investigation into the pricing of unproven Biogen Alzheimer’s treatment Aduhelm by Representative Frank Pallone (D-NJ), Chairman of the U.S. House Committee on Energy and Commerce, and Representative Carolyn Maloney (D-NY), Chairwoman of the House Committee on Oversight and Reform.

“CSRxP applauds Chairman Pallone and Chairwoman Maloney for their commitment to getting answers on the egregious pricing of this unproven treatment by a Big Pharma company that stands to make billions of dollars,” said CSRxP executive director Lauren Aronson. “This investigation will shine an important light on Biogen’s pricing of this drug of questionable efficacy and contribute to the growing momentum in Congress to hold Big Pharma accountable.”

Read more on the coverage of the Aduhelm controversy that highlights outcry over the massive price tag for the unproven treatment, as well as projected cost to taxpayers and the health system HERE.

Read more on what patient advocates, physicians and researchers, clinical experts, drug pricing advocates and even Wall Street analysts have had to say on the Aduhelm controversy HERE.

Read CSRxP’s statement on the U.S. Food and Drug Administration (FDA) approval of Aduhelm and Biogen’s subsequent pricing HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.

###